SynAct Pharma AB Company Description

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden.

The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency.

It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.

SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.

SynAct Pharma AB

Country	Sweden
Founded	2012
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Jeppe Ovlesen

Contact Details

Address: Medicon Village Lund, 223 81 Sweden
Phone	46 1 03 00 10 23
Website	synactpharma.com

Stock Details

Ticker Symbol	SYNACT
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0008241491
SIC Code	2836

Key Executives

Name	Position
Jeppe Ovli Ovlesen EE, MBA	Chief Executive Officer and Director
Bjorn Westberg	Chief Financial Officer
Dr. Thomas Boesen Ph.D.	Chief Operating Officer
James Knight M.B.A.	Chief Business Officer
Kristen Harting M.D.	Chief Medical Officer